Opportunities and Challenges in Translational Research: The Development of Photodynamic Therapy and Anti-Vascular Endothelial Growth Factor Drugs-Reference-Cited by-同舟云学术

Opportunities and Challenges in Translational Research: The Development of Photodynamic Therapy and Anti-Vascular Endothelial Growth Factor Drugs

Published:2021 Issue:1 Volume:49 Page:19-24
ISSN:1073-1105
Container-title:Journal of Law, Medicine & Ethics
language:en
Short-container-title:J. Law. Med. Ethics

Author:

Marko Christina Kaiser,Miller Joan W.

Abstract

AbstractThe development of photodynamic therapy and anti-vascular endothelial growth factor agents have revolutionized the treatment of retinal diseases, transforming the retina subspecialty by ushering in an age of pharmacological treatments for a wide range of diseases, including age-related macular degeneration (AMD).

Publisher

Cambridge University Press (CUP)

Subject

Health Policy,General Medicine,Issues, ethics and legal aspects

Reference30 articles.

1. GUIDELINES FOR USING VERTEPORFIN (VISUDYNE®) IN PHOTODYNAMIC THERAPY TO TREAT CHOROIDAL NEOVASCULARIZATION DUE TO AGE-RELATED MACULAR DEGENERATION AND OTHER CAUSES

2. Ranibizumab versus Bevacizumab to Treat Neovascular Age-related Macular Degeneration

3. Laser Photocoagulation of Subfoveal Neovascular Lesions in Age-Related Macular Degeneration

4. Vascular Endothelial Growth Factor in Ocular Fluid of Patients with Diabetic Retinopathy and Other Retinal Disorders

5. Ranibizumab for Neovascular Age-Related Macular Degeneration

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Unveiling the potential of combining photodynamic with anti-vascular therapy for cancer treatment;Nanophototherapy;2025

2. INTRODUCTION: Public Sector and Non-Profit Contributions to Drug Development — Historical Scope, Opportunities, and Challenges;Journal of Law, Medicine & Ethics;2021